L3VLUP
ProSign in

NVST · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVSTJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVST
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterNVSTJNJ
Q3 20209 holders, $873m30 holders, $26.2bn
Q4 202011 holders, $1.4bn32 holders, $26.6bn
Q1 202113 holders, $2.4bn31 holders, $25.3bn
Q2 202116 holders, $2.1bn37 holders, $25.6bn
Q3 20219 holders, $1.4bn40 holders, $24.1bn
Q4 20217 holders, $1.6bn33 holders, $25.2bn
Q1 202210 holders, $2.3bn35 holders, $28.2bn
Q2 20229 holders, $1.8bn33 holders, $26.9bn
Q3 202211 holders, $1.4bn36 holders, $25.4bn
Q4 20229 holders, $812m35 holders, $27.6bn
Q1 202311 holders, $1.2bn42 holders, $24.5bn
Q2 202311 holders, $868m38 holders, $25.0bn
Q3 20239 holders, $694m37 holders, $18.9bn
Q4 202312 holders, $714m31 holders, $19.0bn
Q1 20249 holders, $393m32 holders, $19.7bn
Q2 20244 holders, $248m35 holders, $20.4bn
Q3 20244 holders, $312m28 holders, $22.3bn
Q4 20244 holders, $301m37 holders, $20.4bn
Q1 20254 holders, $263m32 holders, $20.5bn
Q2 20256 holders, $432m31 holders, $18.4bn
Q3 20255 holders, $359m32 holders, $23.7bn
Q4 20255 holders, $339m29 holders, $27.8bn
Q1 20268 holders, $392m34 holders, $35.6bn
Q2 20269 holders, $577m33 holders, $39.1bn
NVST

Envista Holdings Corporation

Holders
6
Reported value
$432m
Buyers
5
Sellers
2

Breadth +3 among 95 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
31
Reported value
$18.4bn
Buyers
15
Sellers
16

Breadth -1 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2025

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVST (3)

ExodusPoint Capital Management LP, Harris Associates LP, Holocene Advisors LP

Only JNJ (28)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →